Trials / Completed
CompletedNCT04215120
Desidustat in the Treatment of Anemia in CKD on Dialysis Patients
A Phase 3, Multicenter, Open-label, Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet Versus Epoetin Alfa Injection for the Treatment of Anemia in Patients With Chronic Kidney Disease (CKD) on Dialysis (DREAM-D)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 392 (actual)
- Sponsor
- Zydus Lifesciences Limited · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A phase 3, multicenter, open-label, randomized, active-controlled study to evaluate the efficacy and safety of Desidustat Tablet versus Epoetin alfa Injection for the treatment of anemia in patients with CKD on dialysis. (DREAM-D)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Desidustat Oral Tablet | Desidustat tablet |
| DRUG | Epoetin Alfa | Epoetin Injection |
Timeline
- Start date
- 2020-01-04
- Primary completion
- 2021-09-02
- Completion
- 2021-09-02
- First posted
- 2020-01-02
- Last updated
- 2021-11-24
Locations
7 sites across 1 country: India
Source: ClinicalTrials.gov record NCT04215120. Inclusion in this directory is not an endorsement.